KDEL-grafted chondroitin sulfate CPD/siBcl-2/CK
Sequence: KDEL
| Experiment Id | EXP002475 |
|---|---|
| Paper | Dual Strategies Based on Golgi Apparatus/Endoplasmic Reticulum Targeting and Anchoring for High-Effi |
| Peptide | KDEL-grafted chondroitin sulfate CPD/siBcl-2/CK |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | KDEL grafting ratio on chondroitin sulfate approximately 11% |
| Rna Concentration | In vivo siRNA dose 1 mg/kg where applicable; exact in vitro siRNA concentration not fully specified for luciferase assay |
| Mixing Ratio | CPD/siRNA/CK prepared by CPD/siRNA complexation followed by coating with KDEL-grafted chondroitin sulfate; C/Gu ratios screened, same strategy as CPD/siRNA/CS |
| Formulation Format | polymer/polysaccharide nanocomplex |
| Formulation Components | Cell-penetrating poly(disulfide) (CPD), siRNA, KDEL-grafted chondroitin sulfate (CK); CK provides CD44-associated targeting/Golgi transport and KDEL-mediated ER-directed sorting |
| Size Nm | 167.20 |
| Zeta Mv | -13.60 |
| Model Scope | in_vivo |
| Model Type | in vivo reporter RNAi assay |
| Cell Lines Or Primary Cells | B16F10-Luc melanoma cells |
| Animal Model | C57BL/6 mice bearing subcutaneous B16F10-Luc tumors |
| Administration Route | intravenous injection; every 2 days for 3 doses |
| Output Type | in vivo reporter knockdown |
| Output Value | Tumor luciferase expression reduced to 33.7 ± 5.7%, significantly lower than CPD/siLuc/CS at 54.1 ± 16.2% |
| Output Units | |
| Output Notes | Functional in vivo reporter knockdown qualifies as delivery_success_class = 1. Cy5-siNC biodistribution showed tumor accumulation, and frozen tumor sections confirmed intratumoral fluorescence. |
| Toxicity Notes | No major organ abnormalities reported in HE staining; blood routine and biochemical markers did not show major treatment-related abnormalities. |
| Curation Notes |